{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:49:27Z","timestamp":1791607767304,"version":"4.3.4"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.8083-26","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:11:59Z","timestamp":1791411119000},"source":"Crossref","is-referenced-by-count":0,"title":["Subdural Hematoma During Lorlatinib-Induced Regression of Leptomeningeal Carcinomatosis with Suspected Dural Involvement in ALK-Positive Lung Adenocarcinoma"],"prefix":"10.2169","author":[{"given":"Taiyo","family":"Kakefuda","sequence":"first","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyoshi","family":"Tomomatsu","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Umemoto","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Horio","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hayama","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Asano","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Oguma","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566, 2007.","DOI":"10.1038\/nature05945"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Gainor JF, Varghese AM, Ou SHI, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 19: 4273-4281, 2013.","DOI":"10.1158\/1078-0432.CCR-13-0318"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Rangachari D, Yamaguchi N, VanderLaan PA, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 88: 108-111, 2015.","DOI":"10.1016\/j.lungcan.2015.01.020"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sun S, Pithavala YK, Martini JF, Chen J. Evaluation of lorlatinib cerebrospinal fluid concentrations in relation to target concentrations for anaplastic lymphoma kinase (ALK) inhibition. J Clin Pharmacol 62: 1170-1176, 2022.","DOI":"10.1002\/jcph.2056"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med 383: 2018-2029, 2020.","DOI":"10.1056\/NEJMoa2027187"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Teraoka S, Hayashi H, Goto Y, et al. Long-term efficacy and safety of lorlatinib in Japanese patients with ALK-positive advanced NSCLC-A brief report from the CROWN study. JTO Clin Res Rep 5: 100632, 2024.","DOI":"10.1016\/j.jtocrr.2024.100632"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Nakashima K, Demura Y, Kurokawa K, et al. Successful treatment with lorlatinib in a patient with meningeal carcinomatosis of ALK-positive non-small cell lung cancer resistant to alectinib and brigatinib: a case report. Med (Baltim) 100: e27385, 2021.","DOI":"10.1097\/MD.0000000000027385"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Sun MG, Kim IY, Kim YJ, et al. Lorlatinib therapy for rapid and dramatic control of brain and spinal leptomeningeal metastases from ALK-positive lung adenocarcinoma. Brain Tumor Res Treat 9: 100-105, 2021.","DOI":"10.14791\/btrt.2021.9.e19"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Fujiwara Y, Masago K, Matsuzawa R, et al. Long-term response of lorlatinib to leptomeningeal metastasis in patients with anaplastic lymphoma kinase fusion positive non-small lung cancer: a case report. Case Rep Oncol 17: 942-949, 2024.","DOI":"10.1159\/000540445"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Bergmann M, Puskas Z, Kuchelmeister K. Subdural hematoma due to dural metastasis: case report and review of the literature. Clin Neurol Neurosurg 94: 235-240, 1992.","DOI":"10.1016\/0303-8467(92)90095-K"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kunii N, Morita A, Yoshikawa G, Kirino T. Subdural hematoma associated with dural metastasis--case report--. Neurol Med Chir (Tokyo) 45: 519-522, 2005.","DOI":"10.2176\/nmc.45.519"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. George KJ, Lau A, Ellis M, Kiehl TR, Fehlings MG. Metastatic coagulopathic subdural hematoma: a dismal prognosis. Surg Neurol Int 3: 60, 2012.","DOI":"10.4103\/2152-7806.97004"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Edlmann E, Giorgi-Coll S, Whitfield PC, Carpenter KLH, Hutchinson PJ. Pathophysiology of chronic subdural haematoma: inflammation, angiogenesis and implications for pharmacotherapy. J Neuroinflammation 14: 108, 2017.","DOI":"10.1186\/s12974-017-0881-y"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Solomon BJ, Liu G, Felip E, et al. Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study. J Clin Oncol 42: 3400-3409, 2024.","DOI":"10.1200\/JCO.24.00581"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol 18: 1590-1599, 2017.","DOI":"10.1016\/S1470-2045(17)30680-0"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Laigle-Donadey F, Taillibert S, Mokhtari K, Hildebrand J, Delattre JY. Dural metastases. J Neurooncol 75: 57-61, 2005.","DOI":"10.1007\/s11060-004-8098-1"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Pahwa B, Tayal A, Chandra A, Das JM. Subdural hematoma due to dural metastasis: a systematic review on frequency, clinical characteristics, and neurosurgical management. J Neurol Surg A Cent Eur Neurosurg 86: 73-84, 2025.","DOI":"10.1055\/s-0044-1782141"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Lyndon D, Lansley JA, Evanson J, Krishnan AS. Dural masses: meningiomas and their mimics. Insights Imaging 10: 11, 2019.","DOI":"10.1186\/s13244-019-0697-7"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Theodotou CB, Shah AH, Ivan ME, Komotar RJ. Subdural hematoma in a patient taking imatinib for GIST: a case report and discussion of risk with other chemotherapeutics. Anti-Cancer Drugs 27: 259-263, 2016.","DOI":"10.1097\/CAD.0000000000000325"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kim MS, Lee DH, Lee YR, et al. A case of subdural hematoma in patient with chronic myeloid leukemia treated with high-dose imatinib mesylate. Korean J Hematol 45: 73-75, 2010.","DOI":"10.5045\/kjh.2010.45.1.73"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Shatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov AV, DeLoughery TG. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost 15: 835-847, 2017.","DOI":"10.1111\/jth.13651"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Huang YJ, Liu SF, Wang CJ, Huang MY. Exacerbated radiodermatitis and bilateral subdural hemorrhage after whole brain irradiation combined with epidermal growth factor receptor tyrosine kinase inhibitors for brain metastases in lung cancer. Lung Cancer 59: 407-410, 2008.","DOI":"10.1016\/j.lungcan.2007.07.015"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Song KW, Rifkind J, Al-Beirouti B, et al. Subdural hematomas during CML therapy with imatinib mesylate. Leuk Lymphoma 45: 1633-1636, 2004.","DOI":"10.1080\/10428190310001615666"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_8083-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:11:35Z","timestamp":1791605495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_8083-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":23,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8083-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"8083-26"}}